We are the creators of the Xeteor Rx Quality Ladder and the Premium vs
Lab interactions Information not available
In the run-in period, all patients, regardless of whether we are randomized to receive lira or placebo later, were subject to a hypocaloric diet and exercise regime, without GLP-1 receptor agonist, with the duration of the period for each patient being the time required to lose 5% of their baseline body weight In the STEP trials (Table 1), designed to evaluate the efficacy and safety of semaglutide 2.4mg (subcutaneous, weekly) in patients with obesity, or excess weight (BMI 27kg/m2) with complications, weight loss of between 15% and 17% was achieved 68 weeks after starting treatment.7678 In one of the trials, weight loss of 10% was reported after 20 weeks of therapy
Colonna doesn't describe GLP-1 pills as automatically safer or more effective than injectables
Large-scale clinical trials and meta-analyses have not found a significant increase in overall cancer risk with GLP-1 receptor agonists
